1.Masood M, Grimm S, El-Bahrawy M, Yagüe E. TMEFF2: A Transmembrane Proteoglycan with Multifaceted Actions in Cancer and Disease. Cancers (Basel). 2020 Dec 21;12(12):3862. doi: 10.3390/cancers12123862. PMID: 33371267; PMCID: PMC7766544.
2.Xie S, Zhang Y, Peng T, Guo J, Cao Y, Guo J, Shi X, Li Y, Liu Y, Qi S, Wang H. TMEFF2 promoter hypermethylation is an unfavorable prognostic marker in gliomas. Cancer Cell Int. 2021 Mar 4;21(1):148. doi: 10.1186/s12935-021-01818-x. PMID: 33663520; PMCID: PMC7931334.
3.Gao L, Nie X, Zheng M, Li X, Guo Q, Liu J, Liu Q, Hao Y, Lin B. TMEFF2 is a novel prognosis signature and target for endometrial carcinoma. Life Sci. 2020 Feb 15;243:116910. doi: 10.1016/j.lfs.2019.116910. Epub 2019 Oct 11. PMID: 31610211.